Lexicon Pharmaceuticals, Inc.
LXRX
$1.40
$0.064.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -50.87% | 2,187.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -50.87% | 2,187.32% | |||
| Cost of Revenue | 1,035.33% | 3.05% | |||
| Gross Profit | -116.85% | 8,057.02% | |||
| SG&A Expenses | -18.70% | -19.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.93% | -6.72% | |||
| Operating Income | -426.20% | 114.55% | |||
| Income Before Tax | -492.65% | 112.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -492.65% | 112.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -492.65% | 112.86% | |||
| EBIT | -426.20% | 114.55% | |||
| EBITDA | -407.67% | 115.34% | |||
| EPS Basic | -490.00% | 112.88% | |||
| Normalized Basic EPS | -492.86% | 112.81% | |||
| EPS Diluted | -490.00% | 112.88% | |||
| Normalized Diluted EPS | -492.86% | 112.81% | |||
| Average Basic Shares Outstanding | 0.03% | 0.34% | |||
| Average Diluted Shares Outstanding | -0.05% | 0.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||